Report of the 6th International Workshop on PET in lymphoma
Cristina Nanni
(1)
,
Anne Ségolène Cottereau
(2)
,
Egesta Lopci
,
Caroline Bodet-Milin
(3)
,
Monica Coronado
,
Barbara Pro
(4)
,
Wong Seog Kim
(5)
,
Judith Trotman
(6)
,
Sally Barrington
,
Ulrich Dührsen
(7)
,
Thierry Vander Borght
(8)
,
Elena Zamagni
,
Françoise Kraeber-Bodéré
(3)
,
Christina Messiou
(9)
,
Alain Rahmouni
(10)
,
Irène Buvat
(11)
,
Marc Andre
(8)
,
Mark Hertzberg
(12)
,
Wim Oyen
(9)
,
Olivier Casasnovas
(13, 14)
,
Stefano Luminari
(15)
,
Laurent Garderet
(16)
,
Françoise Montravers
(2)
,
Carsten Kobe
(17)
,
Regine Kluge
(18)
,
Annibale Versari
,
Emanuele Zucca
,
Philippe Moreau
(19)
,
Bruce Cheson
(20)
,
Corinne Haioun
(10)
,
Andrea Gallamini
(21)
,
Michel Meignan
(10)
1
UNIBO -
Alma Mater Studiorum Università di Bologna = University of Bologna
2 CHU Tenon [AP-HP]
3 Service de Médecine Nucléaire [Nantes]
4 [Northwestern University Medical School] - Feinberg School of Medicine [Northwestern University, Evanston]
5 Samsung Medical Center Sungkyunkwan University School of Medicine
6 Concord Hospital
7 AöR - University Hospital Essen
8 CHU UCL Namur
9 Royal Marsden Hospital
10 Service de Radiologie [Mondor]
11 IMIV - U1023 - ERL9218 - Imagerie Moléculaire in Vivo
12 Prince of Wales Medical Research Institute
13 Service d'Hématologie Clinique (CHU de Dijon)
14 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
15 IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia
16 CHU Saint-Antoine [AP-HP]
17 University Hospital of Cologne [Cologne]
18 Leipzig University / Universität Leipzig
19 Service d'Hématologie [Nantes]
20 Lombardi Comprehensive Cancer Center
21 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
2 CHU Tenon [AP-HP]
3 Service de Médecine Nucléaire [Nantes]
4 [Northwestern University Medical School] - Feinberg School of Medicine [Northwestern University, Evanston]
5 Samsung Medical Center Sungkyunkwan University School of Medicine
6 Concord Hospital
7 AöR - University Hospital Essen
8 CHU UCL Namur
9 Royal Marsden Hospital
10 Service de Radiologie [Mondor]
11 IMIV - U1023 - ERL9218 - Imagerie Moléculaire in Vivo
12 Prince of Wales Medical Research Institute
13 Service d'Hématologie Clinique (CHU de Dijon)
14 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
15 IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia
16 CHU Saint-Antoine [AP-HP]
17 University Hospital of Cologne [Cologne]
18 Leipzig University / Universität Leipzig
19 Service d'Hématologie [Nantes]
20 Lombardi Comprehensive Cancer Center
21 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
Egesta Lopci
- Fonction : Auteur
Caroline Bodet-Milin
- Fonction : Auteur
- PersonId : 763128
- ORCID : 0000-0002-8219-3592
Monica Coronado
- Fonction : Auteur
Sally Barrington
- Fonction : Auteur
Elena Zamagni
- Fonction : Auteur
- PersonId : 786216
- ORCID : 0000-0003-1422-7305
Irène Buvat
- Fonction : Auteur
- PersonId : 742212
- IdHAL : irene-buvat
- ORCID : 0000-0002-7053-6471
- IdRef : 09504292X
Annibale Versari
- Fonction : Auteur
Emanuele Zucca
- Fonction : Auteur
Résumé
Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented. For the first time, specialists in the field of multiple myeloma (MM) were involved in the expert session. The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging. The meeting dedicated an entire session to MM imaging followed by a session on the role of PET in Peripheral T cell Lymphoma. An entire session addressed the issues of Deauville scale particularly for end treatment assessment and the challenging consequences of immunomodulatory treatments on PET reporting. A specific session presented the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories and the main results obtained in different lymphoma entities were described. Whether it could replace clinical staging has been extensively discussed. The more recent results obtained in the H10 trial have been presented and compared to the published data in early stage Hodgkin lymphoma. Finally, the ongoing studies using PET for guiding therapeutic strategies have been reported by the various lymphoma cooperative groups that participated to the meeting.